LifeSplice Pharma is an early-stage biotech company that develops extraordinarily specific, potent and long-lasting RNA-based drugs called ‘Splice Modulating Oligomers’ (SMOs) to treat severe neurological and non-neurological diseases with critical unment medical needs.  The LifeSplice platform technology relies upon innovative and cost-effective in-silico drug design, validated by its founding scientists, that allows for extremely rapid discovery of new SMO product candidates.

LifeSplice has licensed exclusive world-wide rights for lead product candidates from Drexel University and has been awarded multiple SBIR grants to support preclinical development of its lead products for the treatment of severe epilepsy and amyotrophic lateral sclerosis (ALS).

LifeSplice will develop its lead products through Phase 1 or 2 clinical trials leveraging substantial non-dilutive grant and foundation support prior to partnering for late stage development and commercialization.